Integrilin Dose Optimization Using Cone Plate Analyzer – What Have We Learned Thus Far

Publisher： Karger

E-ISSN： 1424-0556|4|3|151-156

ISSN： 1422-9528

Source： Heart Drug, Vol.4, Iss.3, 2004-08, pp. : 151-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Myc - What We have Learned from Flies

By  

Current Drug Targets, Vol. 10, Iss. 7, 2009-07 ,pp. : 590-601

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Insights into Sepsis: What have we Learned and How will it Help?

By  

Current Pharmaceutical Design, Vol. 14, Iss. 19, 2008-07 ,pp. : 1900-1911

Bentham Science Publishers

Access to resources Recommend Favorite

CCR1 Antagonists: What Have We Learned From Clinical Trials

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 13, 2010-09 ,pp. : 1268-1277

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomic genome-wide association studies: lessons learned thus far

By Crowley James J   Sullivan Patrick F   McLeod Howard L  

Pharmacogenomics, Vol. 10, Iss. 2, 2009-02 ,pp. : 161-163

Future Medicine

Access to resources Recommend Favorite

The Heart and Estrogen/Progestin Replacement Study: What Have We Learned and What Questions Remain?

By Wells G.   Herrington D.M.  

Drugs & Aging, Vol. 15, Iss. 6, 1999-12 ,pp. : 419-422

Adis International

Access to resources Recommend Favorite